European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs